<DOC>
	<DOCNO>NCT01039805</DOCNO>
	<brief_summary>The aim MOT112571 ass pharmacodynamic effect , safety , tolerability , pharmacokinetics , potential therapeutic benefit single dose GSK962040 critically ill patient delay gastric empty intolerant enteral feeding .</brief_summary>
	<brief_title>Evaluation Single Doses GSK962040 Critically Ill Patients With Enteral Feed Intolerance</brief_title>
	<detailed_description />
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Gastroparesis</mesh_term>
	<criteria>Male female 1885 year age , time consent obtain . Mechanically ventilated Intensive Care Unit become intolerant nasogastric enteral feeding . intolerance nasogastric tube feeding define gastric aspirate volume ( GRV ) &gt; 250 mL least 6 hour commence feed &gt; 40 mL/hr . Expected remain mechanically ventilate least 48 hour enrollment expect survive least 24 hour post dose study medication . Subject nasogastric tube enteral feeding . Body weight &gt; = 50 kg Written inform consent may obtain legally acceptable representative , include compliance requirement restriction list consent form . In case , consent seek next kin subject competent give consent . Average QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . AST ALT &lt; 3xULN ; alkaline phosphatase bilirubin &lt; = 2xULN . Subjects rapidly rise aminotransferase whem plausible explanation observe elevation enrol LFTs check eligibility screen prior dose GSK962040 . Subjects receive gastric prokinetic agent previous 24 h ( e.g. , erythromycin , azithromycin , metoclopramide ) . These agent prohibit duration study . Subjects whose clinical condition deteriorate rapidly subject investigator consider reasonable expectation able complete study . Subjects know infected Hepatitis B , Hepatitis C , HIV viruses . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prohibit medication list Section 9.2 within restrict timeframe relative dosing study medication . Subjects renal failure require replacement therapy ( dialysis filtration ) . Subjects reason admission ICU overdose ( deliberate accidental ; medicinal product ) . Subjects alter upper gastrointestinal tract anatomy subject undergone upper gastrointestinal tract surgery admission ICU . Subjects bowel obstruction perforation . Subject gastric pacemaker Subject receive parenteral feed History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Pregnant female determine positive serum urine hCG test screen prior dosing . Lactating female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GSK962040</keyword>
	<keyword>13C octanoic acid breath test</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>critically ill patient</keyword>
	<keyword>gut motility</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>tolerability</keyword>
	<keyword>single dose</keyword>
	<keyword>gastric emtpying</keyword>
</DOC>